# The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications

> **NCT04435015** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Yale University**

## Conditions studied

- Coagulopathy
- Cardiovascular Complication
- COVID-19

## Interventions

- **DRUG:** Camostat Mesylate
- **DRUG:** Microcrystalline Cellulose, NF

## Key facts

- **NCT ID:** NCT04435015
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No funding
- **Last updated:** 2022-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04435015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04435015, "The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04435015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*